RxDoctor Payments Data

Matthew Emanuel, MD

Ophthalmology · Dallas, TXNPI 1487986170

Payments from drug & device makers

$201,312in general payments, 2019–2025

Across 296 payments — averaging $680.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alcon Research LLC$109K
  • Ivantis, Inc$45K
  • Aerie Pharmaceuticals, Inc.$44K
  • AbbVie$2K
  • Glaukos Corporation$398
  • Alcon$339
  • plus $989 from 13 others

What the payments were for

  • Consulting fees$6,26713%
  • Speaking & faculty fees$32,32768%
  • Travel & lodging$4,0208%
  • Food & beverage$4,67110%
  • Gifts$1000%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$201,312 in reported general payments places this provider in the 90th percentile of 1,355 ophthalmology providers in Texas.

See all ophthalmology providers in Texas

Medicare billing

Part B allowed, 2024
$477,570
Medicare patients
944
Services billed
4,966

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LumiganBimatoprost196$91,084
CombiganBrimonidine Tartrate/Timolol136$46,988
RocklatanNetarsudil Mesylat/Latanoprost94$42,006
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol251$36,490
RhopressaNetarsudil Mesylate53$26,924
Prednisolone Acetate516$25,937
XiidraLifitegrast17$24,120
Brimonidine Tartrate635$21,276
SimbrinzaBrinzolamide/Brimonidine Tart72$20,410
VyzultaLatanoprostene Bunod57$19,936
Latanoprost2,098$18,909
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat1,241$18,619
Travoprost106$15,258
Alphagan PBrimonidine Tartrate42$13,142
RestasisCyclosporine13$13,042

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLumigan, Combigan, Alphagan P, Restasis$1,790$164,256387 claims
Aerie Pharmaceuticals, Inc.Rocklatan, Rhopressa$43,768$68,930147 claims
Bausch & Lomb Americas Inc.Xiidra, Vyzulta$159$44,05674 claims
AlconSimbrinza$339$20,41072 claims
Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate$68$4,39023 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,355 ophthalmology providers in Texas.

Other ophthalmology in Dallas

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →